Solara Active Pharma Sciences Limited SOLARAshare price and chart
Solara Active Pharma Sciences closed at ₹640.60 on 19 November 2026, down 1.52% on the day. The 52-week range is ₹422.00 to ₹774.00.
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on SOLARA
Real prices, every charge counted. Pick one or write your own.Solara Active Pharma Sciences designs and makes active pharmaceutical ingredients, including complex and polymer-based APIs, 100% of its turnover, from six plants, for generic and innovator drug makers in 64 countries. Exports are 52% of turnover.
Pharmaceuticals & Biotechnology
APIs
Generic and innovator pharma companies
Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 19 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026Against its sectorWhere this company ranks among similar companies on each measure.
Pharmaceuticals · 141 peers · mediansWhat the numbers sayShort plain statements about this company's latest figures.
Written by fixed rulesLatest quarterIn the quarter to September 2026 (results filed 16 Oct 2026), sales rose 33.1% from a year earlier to ₹417 cr and profit turned positive at ₹28.5 cr after a loss of ₹10.1 cr a year earlier.
- Operating margin rose from 9.3% in FY23 to 13.6% in FY26.
- Debt to equity fell 2 years running (1.07 to 0.53).
- Promoter holding rose 4.7 points over 7 quarters (37.23% to 41.93%).
- Reported a loss in FY24 and FY26.
- Profit before interest covered interest 0.9 times in FY26 (₹95 cr of interest).
- Return on equity stayed under 10% from FY24 to FY26 (highest 0.1%).
- Promoters had pledged 52.0% of their shares at the end of September 2026, 21.81% of all shares.
- Foreign institutions cut their holding by 3.5 points over 5 quarters (14.25% to 10.71%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Share price reaction to resultsWhat the share price did around each recent quarterly result.
Over the last 20 results, the share rose on 4 and fell on 16, and moved by 3% or more on 14.
Q2 FY27: results filed 16 Oct 2026. The share went from its close on 15 Oct 2026 to its close on 19 Oct 2026 -0.49%.
Dividend historyCash the company has paid per share, year by year.
2021 paid ₹3.00 per share, about ₹468 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsHeld for 5 years this compounded at -7.8% a year. The last twelve months were up +12.4%. Price only, before dividends.
Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Who owns itEach line is that holder's share of all shares over the last 7 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Insider tradesPurchases and sales of the company's own shares by promoters, directors and senior staff.
Last 18 monthsRecent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsKey ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorPeers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Revenue and profit, year by yearSales and net profit by financial year or by quarter.
Sales and net profitWhere every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.
FY26In FY26, of every ₹100 of sales it kept ₹0.0 as profit.
How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.
Compounded a yearCash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
Where the cash wentIn FY26 cash rose by ₹1 Cr, after ₹53 Cr spent on plant and equipment.
Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.
| Measure | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales growthSales in this financial year against the previous one. | 13.8% | -8.2% | -3.2% | 6.6% |
| Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax. | 9.3% | -7.2% | 16.1% | 13.6% |
| Net marginOf every ₹100 of sales in the year, how much was left as profit after everything. | -1.5% | -42.8% | 0.0% | -0.5% |
| ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | -1.5% | -46.5% | 0.1% | -0.6% |
| ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders. | 1.8% | -17.3% | 6.1% | 4.6% |
| Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | 0.67x | 1.07x | 0.71x | 0.53x |
| Interest coverHow many times the company's profit before interest could pay its interest bill. | 0.5x | -3.6x | 1.0x | 0.9x |
Each row against this company's own usual level: green better, red worse, grey close to it.
Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.
Pharmaceuticals| Company | What the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality. | How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit. | The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business. | How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | How much operating profit the company made on all the money in the business, whether it came from owners or lenders. | Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | Of every ₹100 of sales, how much is left as profit after all costs, interest and tax. | How much sales grew in the latest quarter against the same quarter a year earlier. | The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share. |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.56 L cr | 41.6x | 5.1x | 14.7% | 19.1% | 0.03 | 17.8% | +11.9% | 0.84% |
| DIVISLAB Divi's Laboratories Limited | 2.97 L cr | 88.2x | 16.5x | 16.2% | 21.5% | 0.00 | 27.6% | +35.4% | 0.27% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.75 L cr | 77.9x | 9.6x | 17.0% | 15.2% | 0.76 | 12.1% | +50.8% | 0.82% |
| LAURUSLABS Laurus Labs Limited | 1.25 L cr | 92.9x | 20.6x | 17.7% | 17.9% | 0.40 | 17.0% | +33.4% | 0.10% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.20 L cr | 28.9x | 4.3x | 18.3% | 19.9% | 0.44 | 14.1% | +29.2% | 0.08% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.17 L cr | 41.7x | 3.0x | 11.5% | 13.9% | 0.15 | 8.3% | -1.5% | 0.57% |
| CIPLA Cipla Limited | 1.15 L cr | 39.5x | 3.2x | 11.7% | 16.0% | 0.01 | 10.1% | -2.4% | 0.92% |
| MANKIND Mankind Pharma Limited | 1.09 L cr | 48.4x | 6.2x | 12.4% | 12.9% | 0.30 | 14.7% | +17.3% | 0.00% |
| AUROPHARMA Aurobindo Pharma Limited | 1.04 L cr | 26.2x | 2.6x | 9.9% | 12.8% | 0.21 | 10.8% | +23.9% | 0.39% |
| LUPIN Lupin Limited | 91,403 cr | 17.6x | 3.8x | 26.9% | 28.8% | 0.23 | 17.0% | +11.1% | 0.90% |
| GLENMARK Glenmark Pharmaceuticals Limited | 73,618 cr | 50.7x | 6.6x | 14.1% | 20.4% | 0.08 | 9.2% | -31.3% | 0.10% |
| ALKEM Alkem Laboratories Limited | 61,516 cr | 29.8x | 4.1x | 17.6% | 20.6% | 0.12 | 13.4% | +13.8% | 1.03% |
| BIOCON Biocon Limited | 59,264 cr | 216.5x | 1.7x | 1.1% | 3.0% | 0.41 | 1.9% | +2.2% | 0.14% |
| ABBOTINDIA Abbott India Limited | 54,600 cr | 33.0x | - | - | - | - | 23.0% | +11.0% | 2.55% |
| GLAND Gland Pharma Limited | 54,336 cr | 43.9x | 5.1x | 10.5% | 15.0% | 0.02 | 17.5% | +23.3% | 0.61% |
| IPCALAB IPCA Laboratories Limited | 47,189 cr | 33.6x | 5.4x | 13.2% | 16.6% | 0.06 | 14.2% | +13.8% | 0.32% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 45,967 cr | 40.6x | 24.4x | 48.9% | 66.5% | 0.00 | 27.6% | +20.8% | 2.10% |
| EMCURE Emcure Pharmaceuticals Limited | 44,481 cr | 40.7x | 8.3x | 19.6% | 24.8% | 0.27 | 10.7% | +24.3% | 0.15% |
| AJANTPHARM Ajanta Pharma Limited | 40,865 cr | 32.4x | 8.4x | 25.4% | 32.7% | 0.02 | 20.3% | +32.5% | 0.98% |
| SAILIFE Sai Life Sciences Limited | 37,985 cr | 100.5x | 14.1x | 15.1% | 20.9% | 0.17 | 15.9% | +22.5% | 0.00% |
| WOCKPHARMA Wockhardt Limited | 35,537 cr | 86.7x | 6.9x | 4.0% | 6.5% | 0.39 | 10.8% | +23.9% | 0.00% |
| ACUTAAS Acutaas Chemicals Limited | 32,561 cr | 74.1x | 17.5x | 23.5% | 31.7% | 0.00 | 27.5% | +42.7% | 0.06% |
| PPLPHARMA Piramal Pharma Limited | 31,906 cr | - | 3.9x | -4.0% | 0.8% | 0.69 | -2.1% | +28.1% | 0.00% |
| RUBICON Rubicon Research Limited | 28,510 cr | 87.3x | 20.1x | 19.1% | 23.4% | 0.28 | 15.5% | +39.9% | 0.09% |
| NEULANDLAB Neuland Laboratories Limited | 27,074 cr | 59.8x | 13.3x | 21.4% | 27.5% | 0.17 | 19.6% | -12.6% | 0.16% |
| APLLTD Alembic Pharmaceuticals Limited | 20,631 cr | 24.4x | 3.5x | 12.4% | 11.7% | 0.25 | 9.9% | +36.3% | 1.14% |
| GRANULES Granules India Limited | 19,853 cr | 27.7x | 3.0x | 13.5% | 15.7% | 0.09 | 12.1% | +20.3% | 0.22% |
| ERIS Eris Lifesciences Limited | 18,418 cr | 25.8x | 4.4x | 18.1% | 13.9% | 0.58 | 21.6% | +12.6% | 0.54% |
| ONESOURCE Onesource Specialty Pharma Limited | 18,381 cr | - | 3.1x | -1.3% | 0.4% | 0.25 | -0.1% | +37.4% | 0.00% |
| ALIVUS Alivus Life Sciences Limited | 17,801 cr | 26.6x | 4.9x | 18.4% | 24.6% | 0.00 | 24.9% | +16.0% | 0.34% |
| SHILPAMED Shilpa Medicare Limited | 17,616 cr | 52.7x | 6.4x | 9.8% | 11.4% | 0.24 | 18.1% | +43.0% | 0.07% |
| PFIZER Pfizer Limited | 17,614 cr | 20.5x | 4.0x | 17.2% | 23.4% | 0.00 | 32.4% | +13.2% | 1.95% |
| COHANCE Cohance Lifesciences Limited | 17,578 cr | 510.5x | 4.5x | 5.1% | 8.0% | 0.06 | -0.3% | -14.2% | 0.00% |
| NATCOPHARM Natco Pharma Limited | 16,124 cr | 17.8x | 1.6x | 16.9% | 17.1% | 0.11 | 26.9% | -29.0% | 0.70% |
| CAPLIPOINT Caplin Point Laboratories Limited | 15,845 cr | 23.0x | 4.1x | 19.9% | 24.7% | 0.00 | 29.4% | +17.9% | 0.38% |
| ASTRAZEN AstraZeneca Pharma India Limited | 15,283 cr | 86.0x | 17.4x | 22.8% | 31.2% | 0.00 | 6.8% | +30.4% | 0.59% |
| JUBLPHARMA Jubilant Pharmova Limited | 14,865 cr | 56.2x | 2.1x | 6.0% | 8.7% | 0.54 | 2.9% | +20.5% | 0.54% |
| CORONA CORONA Remedies Limited | 13,680 cr | 66.1x | 17.0x | 24.8% | 27.8% | 0.12 | 13.3% | +22.2% | 0.45% |
| MARKSANS Marksans Pharma Limited | 13,556 cr | 24.2x | 4.1x | 25.4% | 35.1% | 0.01 | 16.7% | +30.5% | 0.30% |
| SOLARA Solara Active Pharma Sciences Limited | 3,079 cr | 83.6x | 2.1x | -0.6% | 4.6% | 0.40 | 2.4% | +33.1% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Month by month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.4 | -8.7 | -7.9 | +16.5 | +7.4 | +8.1 | -10.8 | +23.2 | +14.7 | -12.8 | +1.3 | · | +13.4% 11m |
| 2025 | -24.5 | -7.8 | +8.6 | -3.8 | -2.6 | +32.5 | +0.8 | -4.5 | -1.6 | -0.5 | -14.3 | +9.9 | -16.8% |
| 2024 | +6.4 | +15.8 | -16.6 | +43.6 | -14.8 | +30.3 | +14.8 | +12.8 | +11.6 | -1.7 | +9.8 | -20.2 | +104.0% |
| 2023 | -4.6 | -12.1 | -9.2 | +15.0 | -6.0 | +7.8 | +4.3 | -9.3 | -1.0 | -14.5 | +10.8 | +6.7 | -16.1% |
| 2022 | -7.7 | -27.2 | -2.7 | -4.0 | -35.0 | -15.1 | +8.6 | +18.1 | -7.7 | -4.4 | +14.9 | -6.0 | -57.8% |
| 2021 | +24.6 | -6.2 | +0.0 | +9.3 | +15.5 | -4.2 | -2.4 | -1.3 | -1.4 | -22.2 | +2.3 | -20.0 | -14.4% |
| 2020 | +6.0 | +35.0 | -28.6 | +31.9 | -11.8 | +28.2 | +14.8 | +22.5 | +15.4 | +5.7 | +2.8 | +1.9 | +174.0% |
| 2019 | +25.3 | -4.8 | +13.1 | -8.3 | +21.6 | -4.3 | -25.5 | +32.3 | -15.0 | +13.3 | +5.2 | -2.5 | +40.2% |
| 2018 | · | · | · | · | · | · | -22.0 | +98.7 | -22.6 | +19.0 | -7.8 | +3.7 | +36.5% 6m |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2026-11-11 | THE SCOTTISH ORIENTAL SMALLER COMPANIES TRUST PLC · bulk | SELL | 5,51,618 | ₹663.78 | ₹36.62 Cr |
| 2026-11-11 | FIRST SENTIER INVESTORS ICVC - SI INDIAN SUBCONTINENT ALL CAP FUND · bulk | BUY | 5,51,618 | ₹663.84 | ₹36.62 Cr |
| 2026-10-16 | JUNOMONETA FINSOL PRIVATE LIMITED · bulk | SELL | 2,60,838 | ₹724.62 | ₹18.90 Cr |
| 2026-10-16 | JUNOMONETA FINSOL PRIVATE LIMITED · bulk | BUY | 2,60,455 | ₹724.53 | ₹18.87 Cr |
| 2026-08-20 | JUNOMONETA FINSOL PRIVATE LIMITED · bulk | BUY | 2,83,420 | ₹626.19 | ₹17.75 Cr |
| 2026-08-20 | JUNOMONETA FINSOL PRIVATE LIMITED · bulk | SELL | 2,82,513 | ₹626.82 | ₹17.71 Cr |
| 2025-06-20 | FSSA INDIAN SUBCONTINENT FUND · bulk | SELL | 2,24,730 | ₹538.11 | ₹12.09 Cr |
| 2025-06-16 | SPIRACCA VENTURES LLP · bulk | SELL | 20,00,000 | ₹495.00 | ₹99.00 Cr |
- Board outcomeOutcome of Board Meeting16 Oct 2026
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, along with the Limited Review Report for the said period.
- Board outcomeOutcome of Board Meeting23 Jul 2026
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report for the said period.
- Board outcomeOutcome of Board Meeting15 May 2026
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the year ended March 31, 2026 and unaudited Financial Results for the quarter ended March 31, 2026, along with the Auditor's...
- Board outcomeOutcome of Board Meeting6 Feb 2026
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, the unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025 along with the Limited Review Report for the said period.
- Board outcomeOutcome of Board Meeting6 Nov 2025
Solara Active Pharma Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
- Board outcomeOutcome of Board Meeting5 Nov 2025
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025 along with the Limited Review Report for the said period.
- Press releasePress Release25 Jul 2025
Solara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated July 25, 2025, titled "Solara Q1'26 performance" of the Board Meeting held today i.e. July 25, 2025, to consider the Financial Results for the quarter ended June 30, 2025.
- Board outcomeOutcome of Board Meeting25 Jul 2025
Solara Active Pharma Sciences Limited has informed the Exchange regarding inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 along with Limited review Report for the said period.
- Press releasePress Release15 May 2025
Solara Active Pharma Sciences Limited, has informed the exchange regarding the Press release in connection with Financial Results for the quarter and year ended March 31, 2025.
- Board outcomeOutcome of Board Meeting15 May 2025
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2025 along with the Auditors Report for the said period.
- Integrated Filing- Financial29 Jan 2025
The Company is hereby submitting the Integrated Filing - Financials for the quarter ended December 31, 2024
- Press releasePress Release24 Jan 2025
Solara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated January 24, 2025, titled "Solara Q3 25 performance" for the Financial Results for the quarter ended December 31, 2024
- Financial Result Updates24 Jan 2025
Solara Active Pharma Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
- Board outcomeOutcome of Board Meeting24 Jan 2025
Solara Active Pharma Sciences Limited has informed the Exchange regarding Board meeting held on January 24, 2025 interalia to consider and approve the Unaudited Financial Results for the quarter ended December 31, 2024 and other matters.
- Board outcomeOutcome of Board Meeting24 Jan 2025
Solara Active Pharma Sciences Limited has informed the Exchange regarding Board meeting held on January 24, 2025 interalia to consider and approve the Unaudited Financial Results for the quarter ended December 31, 2024 and other matters.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test SOLARA. “Buy SOLARA when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free